Moderna is trading 4.6% down now at $142.81 after announcing a proposed $2 billion private placement of convertible senior notes due 2032.
- The notes may be increased by $300 million, with proceeds for oncology investment, general corporate purposes, and debt repayment.
- Investors may be reacting to potential dilution and financing timing after recent cancer-vaccine rally; profit-taking and valuation concerns follow Modernaβs extraordinary Phase 3 melanoma-vaccine-driven rally.
- Broader markets are higher, making company-specific financing news the clearest explanation.